Showing 1191-1200 of 1361 results for "".
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Layoffs at Medicis top 300, with 117 staffers chosen to stayhttps://practicaldermatology.com/news/20130104-layoffs_at_medicis_top_300_with_117_staffers_chosen_to_stay/2459648/The layoff toll at Medicis Pharmaceutical has topped 300, the Phoenix Business Journal reports. Valeant Pharmaceuticals ($VRX), which wrapped up its buyout of the Arizona-based skin drug company last week, has cut 319 staffers--and kept 117--as it integrates Medicis into its own dermatology operatio
- Valeant Pharmaceuticals Appoints New Managementhttps://practicaldermatology.com/news/20130103-valeant_pharmaceuticals_appoints_new_management/2459649/Valeant Pharmaceuticals International, Inc. named Laizer D. Kornwasser the Executive Vice President/Company Group Chairman, where he will be responsible for operations in Canada, US Neurology, and managed care and distribution, effective February
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- CryoShape Uses Cold to Reduce Scarshttps://practicaldermatology.com/news/20121203-cryoshape_uses_cold_to_reduce_scars/2459667/CryoShape is a patented handheld device for treating keloid and hypertrophic scars. Physicians can destroy deep tissue using an extremely cold probe that is injected directly into the scar. Treating scars with cold freezes them from the inside,
- Grants Awarded from National Rosacea Societyhttps://practicaldermatology.com/news/20121127-grants_awarded_from_national_rosacea_society/2459673/The National Rosacea Society (NRS) awarded funding to five new studies as part of its research grants program to increase knowledge and understanding of rosacea. Dr. Anna Di Nardo, associate professor of medicine at the University of California-San Diego, received $25,000 to study the role of mast c
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- ADCS Acquires More Clinicshttps://practicaldermatology.com/news/20121106-adcs_acquires_more_clinics/2459683/After announcing a major acquisition of multiple clinics on Florida's West Coast, Advanced Dermatology & Cosmetic Surgery (ADCS) has acquired two clinics in the Florida Keys from the practice of Dr. Karen Weismantle. The clinics are
- Janssen to Develop, Commercialize JAK Inhibitor For Immunological Diseaseshttps://practicaldermatology.com/news/20121002-janssen_to_develop_commercialize_jak_inhibitor_for_immunological_diseases/2459720/Janssen Biotech, Inc. entered into a license agreement with Astellas Pharma Inc. for the worldwide development and commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor. ASP015K is currently in Phase 2b development as a once-daily oral treatment for mod
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree